Guidelines for Shared Maternity Care Affiliates 2021 Guidelines for Shared Maternity Care Affiliates 2021

Total Page:16

File Type:pdf, Size:1020Kb

Guidelines for Shared Maternity Care Affiliates 2021 Guidelines for Shared Maternity Care Affiliates 2021 GUIDELINES FOR SHARED MATERNITY CARE AFFILIATES 2021 GUIDELINES FOR SHARED MATERNITY CARE AFFILIATES 2021 The Royal Women’s Hospital Mercy Public Hospitals Incorporated Western Health Northern Health Disclaimer Guidelines for Shared Maternity Care Affiliates 2021 These Guidelines have been developed for the provision of Copyright State of Victoria 2021 shared maternity care between The Royal Women’s Hospital, Mercy Public Hospitals Incorporated, Western Health and © Copyright State of Victoria 2021 The Royal Women’s Northern Health (the Hospitals) and shared maternity care Hospital, Mercy Public Hospitals Incorporated, Western Health affiliates credentialed at these hospitals. and Northern Health. All rights reserved. Irrespective of these Guidelines, every health service provider Except for fair dealing for the purposes of research, education and health professional must individually exercise the standard or study, no part of this document may be reproduced and/ of professional judgment and conduct expected of them in or redistributed, in whole or in part, for any other purpose. selecting the most appropriate care for a pregnant woman and Where this document is reproduced and/or redistributed for in the management of her pregnancy. the purposes of research, education or study, the following statement must appear: Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or © 2021 Guidelines for Shared Maternity Care Affiliates: The service is expressly negatived. The Hospitals cannot and do Royal Women’s Hospital, Mercy Public Hospitals Incorporated, not warrant that the information contained in these guidelines Western Health and Northern Health. This work is reproduced is in every respect accurate, complete or indeed appropriate and distributed with the permission of The Royal Women’s for every woman and her pregnancy. Hospital, Mercy Public Hospitals Incorporated, Western Health and Northern Health. No other use is permitted. The Hospitals accept no responsibility for the completeness or accuracy of any of the information contained in or accessed March 2021 in these Guidelines and makes no representations about their suitability for any particular purpose. Suggested citation: Guidelines for Shared Maternity Care Affiliates 2021, The Royal Women’s Hospital, Mercy Public While the Hospitals make every effort to ensure that the Hospitals Incorporated, Western Health and Northern Health, information is accurate and comprehensive, the information Melbourne, 2021. is only intended as a guide, and may not address particular circumstances. Our acknowledgment and thanks to North Western Melbourne PHN, who provided funding and support for the development To the extent permitted by law, the Hospitals exclude all liability of these guidelines. for loss or damage arising from the use of, or reliance on, the information contained in or accessed in these Guidelines This publication is available on the hospital websites: whether or not caused by any negligence on the part of the www.thewomens.org.au Hospitals or their agents. www.mercyhealth.com.au www.westernhealth.org.au These Guidelines contain links to websites not under the direct www.nh.org.au control of the Hospitals (Linked Sites). These Linked Sites are www.nwmphn.org.au provided as a convenience and the inclusion of any link does not imply endorsement or approval of the Linked Site. The Hospitals make no warranty regarding the quality, accuracy, currency or fitness for purpose of the content or services available through Linked Sites. Guidelines for Shared Maternity Care Affiliates 2021 2. CONTENTS Disclaimer 2 Guideline Development Group 7 Acknowledgments 8 Abbreviations 9 Preface 11 Chapter 1: Maternity care at the hospitals 12 Scope of maternity care 13 Referring to hospital 15 Hospital satellite clinics 17 Childbirth education and hospital tours 17 Chapter 2: Pre-pregnancy consultation 18 Pre-pregnancy care 19 Pre-pregnancy checklist 25 Resources 26 Chapter 3: Shared maternity care 27 Credentialing 28 Responsibilities 29 Shared maternity care coordinators 30 Suitability for shared maternity care 31 Modified shared maternity care 33 Cessation of shared care 37 Patient-held pregnancy record 38 Resources 38 Chapter 4. Antenatal visits 39 Standard antenatal consultation and examination 40 Consultation discussion points 41 Common first trimester interventions: Aspirin and high dose folate 43 Schedule of visits: timing and place 44 Hospital visits schedule and care 45 Chapter 5: Maternal antenatal investigations 51 Initial routine investigations in first trimester 52 Other initial investigations to consider 55 CONTENTS Second trimester investigations: 26-28 weeks 57 Third trimester investigations 57 Screening tests not generally recommended 58 Repeating tests 58 Antenatal investigation summary 59 Resources 62 Chapter 6: Screening for fetal chromosomal and structural anomalies 63 Chromosomal screening 64 Down syndrome / other aneuploidies 66 Fetal structural anomalies 70 Diagnostic tests for chromosomal abnormalities 71 Resources 72 Chapter 7: Fetal chromosomal and structural anomalies 73 Fetal chromosomal and structural abnormal findings 74 High-risk aneuploidy screening result 74 Fetal abnormality on ultrasound and ultrasound markers 75 Abortion for fetal abnormality 77 Chapter 8: Fetal movement, growth and placental concerns 78 Decreased fetal movements 79 Fetal growth concerns 79 Common placenta abnormalities 81 Low-lying placenta and Placenta praevia 81 Vasa praevia 82 Cord issues 82 Placental Adhesion Disorders: accreta, increta and percreta 83 Resources 83 Chapter 9: Immunisation in pregnancy 84 Routinely recommended vaccinations 85 Not routinely recommended vaccinations: consider if high risk 87 Contraindicated vaccinations 87 Summary vaccination in pregnancy 88 Postnatal vaccines 88 CONTENTS Resources 88 Chapter 10: Rh and other Blood Antibodies 89 Rh D immunoglobulin (anti-D) 90 Other blood antibodies 91 Resources 91 Chapter 11: Labour and delivery 92 Trial of labour after caesarean section 93 Induction of labour 95 External Cephalic Version and Breech Delivery 96 Resources 97 Chapter 12: Aspirin, calcium and heparin 98 Aspirin 99 Low molecular weight heparin 100 Resources 100 Chapter 13: Common maternal conditions 101 Medicines in pregnancy 102 Hypertensive disorders 104 Hypothyroidism 105 Diabetes 107 Asthma 107 Rhinitis 108 Anaemia 110 Iron deficiency anaemia 110 Vitamin B12 Deficiency 113 Vitamin D Deficiency 113 Thalassemia 113 Infectious diseases 114 Skin changes and dermatoses 118 Resources 120 Chapter 14: Nutrition and lifestyle 122 Nutrition and Food safety 123 Recommended Supplements 125 CONTENTS Infections 126 Travel advice 126 Exercise 128 Alcohol and tobacco use in pregnancy 129 Resources 131 Chapter 15: Mental health and wellbeing 132 Risk factors 133 Screening 133 Management principles for depression 135 Mental health services 136 Mother and baby mental health services 139 Child protection and support services 140 Child and family services and support 140 Perinatal Psychotropic Medicines Information Service 140 Domestic violence 141 Resources 143 Chapter 16: Postnatal care 144 In hospital 145 In the community 146 Follow-up common maternal issues 148 Postnatal advice 150 Postnatal vaccination 151 Breastfeeding 151 Postnatal support and contact details 152 Maternal child health support services 152 Resources 153 Chapter 17: Hospital services and contacts 154 Chapter 18: Patient Resources 169 Appendix 1: Hospital contact details 178 GUIDELINE DEVELOPMENT GROUP Main Author & Project Lead Western Health Dr Ines Rio Dr Jo Silva Head General Practice Liaison Unit and Senior Medical Staff, General Practice Advisor The Royal Women’s Hospital Dr Elske Posma Obstetrics Unit Head Project Officer Jennifer Patterson Vasvi Kapadia Midwifery Unit Head General Practice Liaison Unit, The Royal Women’s Hospital Endorsed: Dr Elske Posma The Royal Women’s Hospital Djerriwarrh Health Dr Ines Rio Head General Practice Liaison Unit and Senior Medical Staff Dr Nisha Khot Director, Maternity Service Prof Mark Umstad Clinical Director, Maternity Services Endorsed: Dr Nisha Khot Dr. Stephen Cole North Western Melbourne Primary Head of Unit - Multiple Pregnancy Clinic and Health Network Shard Maternity Care Bianca Bell Trish Ryan Director, Primary Care Practice Midwifery Team Leader Dr Len Matthews Royal Australian College of General Practitioners Obstetrics Lead, Sandringham (RACGP) Fay Presbury Dr Sarah Lewis Midwife Lead, Sandringham General Practitioner Endorsed: A/Prof Mark Umstad Clinical Director, Maternity Services Shared Maternity Care Affiliates (General Practitioners) Mercy Public Hospitals Incorporated Dr Jane Doyle Dr Mary Anne McLean Dr Lauren Ong General Practice Liaison Medical Advisor Dr Natalia Rhode Dr Gillian Paulsen Maternity Unit Head, Heidelberg Dr Tamsin Rhodes Dr Jacqueline Van Dam Dr Angela Rutherford Director of Maternity Services, Werribee Mercy Hospital Endorsed: Dr Gillian Paulsen and Dr Jacqueline Van Dam Shared Maternity Care Affiliates (Midwives) Helen Ireland Northern Health Cindy Scott Dr Paul Howat Maternity Unit Head Dr Khalid Arzoo Obstetrics Unit Head Julie Kane Midwifery Director Endorsed: Dr Paul Howat Guidelines for Shared Maternity Care Affiliates 2021 7. ACKNOWLEDGMENTS Dr Helen Savoia The reviewing Shared Maternity Care Affiliates: Consultant Haematologist, The Royal Women’s Hospital Dr Luma Alkhayat Dr Michelle Giles Dr Ralph Audehm Physician, Microbiology and Infectious Diseases,
Recommended publications
  • Impetigo Herpetiformis: a Case Report
    Perinatal Journal • Vol: 13, Issue: 4/December 2005 227 Impetigo Herpetiformis: A Case Report ‹ncim Bezircio¤lu1, Merve Biçer1, Levent Karc›1, Füsun Özder2, Ali Balo¤lu1 1First Clinic of Gynecology and Obstetrics, 2Clinics of Dermatology, Atatürk Training and Research Hospital, ‹zmir Abstract Objective: Impetigo herpetiformis is a rare and potentially life-threatening pustular dermatosis affecting mainly pregnant women. We report here a case of impetigo herpetiformis which occured in twenty-ninth week of pregnancy. Case: A 32 year old gravida 2, para1 pregnant woman who was referred to our institution because of congestive heart failure, gestational diabetes mellitus and oligohidroamnios in 27th gestational age was hospitalized. Eruptive pustular lesions which appeared in 29th week of the gestation has spread her entire body. Her pustular cultures were negative. A punch skin biopsy from a pustule on the trunk made the diagnosis of impetigo herpetiformis. The patient who developed spontaneous uterine contractions was treated with betamethazone and tocolysis. The patient who did not respond to this treatment was taken to delivery at 30 weeks of gestation.The newborn showed no skin lesions after birth. The skin lesions of the mother improved in the second postpartum week. Conclusion: The rates of maternal mortality and fetal mortality and morbidity due to placental insufficiency are increased in impetigo herpetiformis. To reduce the mortality and morbidity rates the antenatal management of impetigo herpetiformis should be organized with a multidisciplinary approach. Keywords: Impetigo herpetiformis, generalized pustular psoriasis. Impetigo herpetiformis: Bir olgu sunumu Amaç: ‹mpetigo herpetiformis gebelerde görülen yaflam› riske edebilen nadir bir püstüler dermatozdur. Bu çal›flmada 29.gebe- lik haftas›nda ortaya ç›kan impetigo herpetiformis olgusu sunulmufltur.
    [Show full text]
  • The Diagnostic Impact of Limited, Screening Obstetric Ultrasound When Performed by Midwives in Rural Uganda
    Journal of Perinatology (2014) 34, 508–512 © 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE The diagnostic impact of limited, screening obstetric ultrasound when performed by midwives in rural Uganda JO Swanson1, MG Kawooya2, DL Swanson1, DS Hippe1, P Dungu-Matovu2 and R Nathan1 OBJECTIVE: To evaluate the diagnostic impact of limited obstetric ultrasound (US) in identifying high-risk pregnancies when used as a screening tool by midwives in rural Uganda. STUDY DESIGN: This was an institutional review board-approved prospective study of expecting mothers in rural Uganda who underwent clinical and US exams as part of their standard antenatal care visit in a local health center in the Isingiro district of Uganda. The midwives documented clinical impressions before performing a limited obstetric US on the same patient. The clinical findings were then compared with the subsequent US findings to determine the diagnostic impact. The midwives were US-naive before participating in the 6-week training course for limited obstetric US. RESULT: Midwife-performed screening obstetric US altered the clinical diagnosis in up to 12% clinical encounters. This diagnostic impact is less (6.7 to 7.4%) if the early third trimester diagnosis of malpresentation is excluded. The quality assurance review of midwives’ imaging demonstrated 100% sensitivity and specificity in the diagnosing gestational number, and 90% sensitivity and 96% specificity in the diagnosis of fetal presentation. CONCLUSION: Limited, screening obstetric US performed by midwives with focused, obstetric US training demonstrates the diagnostic impact for identifying conditions associated with high-risk pregnancies in 6.7 to 12% of patients screened.
    [Show full text]
  • Placenta Praevia/Low-Lying Placenta
    LOCAL OPERATING PROCEDURE – CLINICAL Approved Quality & Patient Safety Committee 18/6/20 Review June 2022 PLACENTA PRAEVIA/LOW-LYING PLACENTA This LOP is developed to guide clinical practice at the Royal Hospital for Women. Individual patient circumstances may mean that practice diverges from this LOP. 1. AIM • Diagnosis and clinical management of woman with low-lying placenta (LLP) or placenta praevia (PP) 2. PATIENT • Pregnant woman with a LLP/PP after 20 weeks gestation 3. STAFF • Medical and midwifery staff 4. EQUIPMENT • Ultrasound • 16-gauge intravenous (IV) cannula • Blood tubes 5. CLINICAL PRACTICE Screening: • Recommend a morphology ultrasound at 18-20 weeks gestation to ascertain placental location • Include, on the ultrasound request form, any history of uterine surgery e.g. previous caesarean section (CS), myomectomy, to ensure that features of placenta accreta are examined • Identify woman with a: o LLP i.e. within 2cm of, but not covering the internal cervical os o PP i.e. covering the internal cervical os Antenatal care: • Reassure woman that 9 out of 10 LLP found at 18-20 week morphology ultrasound are no longer low-lying by term1 • Reassure woman with LLP that if she remains asymptomatic, there is no increased risk of adverse outcomes in the mid-trimester and she can continue normal activities e.g. travel, intercourse, exercise2 • Advise woman with LLP from 36 weeks that it is not a contraindication for trial of labour, chance of vaginal birth approximately9: o 43% if placenta is 0-10mm from cervical os o 85% if placenta
    [Show full text]
  • Background on Multiple Births
    National Maternity and Perinatal Audit NHS Maternity Care for Women with Multiple Births and Their Babies A study on feasibility of assessing care using data from births between 1 April 2015 and 31 March 2017 in England, Wales and Scotland The National Maternity and Perinatal Audit (NMPA) is led by the Royal College of Obstetricians and Gynaecologists (RCOG) in partnership with the Royal College of Midwives (RCM), the Royal College of Paediatrics and Child Health (RCPCH) and the London School of Hygiene and Tropical Medicine (LSHTM). The NMPA is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) on behalf of NHS England, the Welsh Government and the Health Department of the Scottish Government. HQIP is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of Nursing, and National Voices. Its aim is to promote quality improvement in patient outcomes, and in particular, to increase the impact that clinical audit, outcome review programmes and registries have on healthcare quality. HQIP holds the contract to commission, manage and develop the NCAPOP, comprising around 40 projects covering care provided to people with a wide range of medical, surgical and mental health conditions. The programme is funded by NHS England, the Welsh Government and, with some individual projects, other devolved administrations and crown dependencies (www.hqip.org.uk/national-programmes). © 2020 Healthcare Quality Improvement Partnership (HQIP)
    [Show full text]
  • 20. Riesgos Y Complicaciones En FIV-ICSI
    01 serono 1-6 OK:Maquetación 1 8/3/07 12:14 Página 223 20. Riesgos y complicaciones en FIV-ICSI RIESGOS DERIVADOS DEL TRATAMIENTO HORMONAL Estimulación ovárica y riesgo de cáncer La medicación para estimular la ovulación se utiliza desde hace unos cuarenta años para tratar la infertilidad. En los últimos veinte años, diferentes estudios empiezan a cuestio- nar la seguridad de estos fármacos y su relación con distintos tipos de cáncer. Ayhan y cols. en una revisión en el año 2004, concluyen que se necesitan estudios prospectivos, multicéntricos y durante largos periodos de tiempo para determinar la relación entre el uso de los fármacos para estimular la ovulación y el riesgo de cáncer(1). En el año 2000, Klip et al. realizan una revisión desde 1966 a 1999 donde se analiza la relación entre el uso de fármacos de estimulación ovárica y el riesgo de cáncer de ova- rio, mama, endometrio, tiroides y melanoma. Aunque se sugiere una relación entre el uso de los fármacos y el riesgo de cáncer, no existen estudios epidemiológicos que lo demues- tren(2). Más tarde, Kashyap et al. 2004, en su metaanálisis, demuestran una tendencia hacia un efecto beneficioso de las técnicas de reproducción asistida, ya que suelen fina- lizar en embarazo, que es un factor protector contra el cáncer de ovario(3). Sin embargo, Ness et al., 2002, publicaron un metaanálisis(4), en el que encontraban un ligero aumento de riesgo de neoplasia borderline en pacientes que habían sido expues- tas a tratamientos de infertilidad, cuando se comparaba con la población normal, pero Mosgaard demostró que ello es debido en parte a la propia infertilidad(5).
    [Show full text]
  • Cohort Study of High Maternal Body Mass Index and the Risk of Adverse Pregnancy and Delivery Outcomes in Scotland
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2018-026168 on 20 February 2020. Downloaded from Cohort study of high maternal body mass index and the risk of adverse pregnancy and delivery outcomes in Scotland Lawrence Doi ,1 Andrew James Williams ,2 Louise Marryat ,3,4 John Frank3,5 To cite: Doi L, Williams AJ, ABSTRACT Strengths and limitations of this study Marryat L, et al. Cohort Objective To examine the association between high study of high maternal maternal weight status and complications during pregnancy ► This study used a large, retrospectively accessed body mass index and the and delivery. risk of adverse pregnancy but cohort- structured, national database covering Setting Scotland. and delivery outcomes some of the major maternal and neonatal outcomes Participants Data from 132 899 first- time singleton in Scotland. BMJ Open in Scotland over eight recent years. deliveries in Scotland between 2008 and 2015 were used. 2020;10:e026168. doi:10.1136/ ► Analyses were adjusted for some of the key potential Women with overweight and obesity were compared with bmjopen-2018-026168 confounders to estimate impact of high maternal- women with normal weight. Associations between maternal ► Prepublication history and weight status on each outcome. body mass index and complications during pregnancy and 2 additional material for this ► All women with body mass index (BMI) of 30 kg/m delivery were evaluated. paper are available online. To or more were considered as having obesity; it is like- Outcome measures Gestational diabetes, gestational view these files, please visit ly that differentiating morbid obesity or obesity class hypertension, pre- eclampsia, placenta praevia, placental the journal online (http:// dx.
    [Show full text]
  • Print) • Page 2 of 5
    Page 1 of 5 Are twins always high risk? • aims.org.uk Are twins always high risk? AIMS Journal, 2011, Vol 23 No 4 Joanne Whistler asks whether they are really a variation on normal After a wonderful home birth with my firstborn, Oliver, in 2006 I felt confident in my body's ability to labour and give birth. Even when I discovered that I was pregnant with twins late last year I had the attitude that it was just a variation on normal. It was only when I started reading up about multiple pregnancy and birth that my belief that I would have another good experience began to falter. Everything I read said that multiple pregnancies were higher risk, that I should expect a more medicalised experience of pregnancy and birth than a mother of a singleton, and implied that for my babies' sake I should give up any thought of what I considered to be a normal birth. Of course I wanted my babies to be safe, but I also wanted their entry into the world to be gentle and unmedicated – I was very aware of the risks and side effects of pharmacological pain relief and interventions such as induction. In the end I had a fabulous home water birth attended by two independent midwives. My husband and a trusted friend were also there. My midwife monitored the babies intermittently and removed the caul from twin two's face but otherwise my labour and birth were completely intervention-free. In this article I will discuss the evidence base for management of multiple pregnancies and explore some aspects of planning the birth of twins or more.
    [Show full text]
  • Thyroid Disease in the Perinatal Period
    Thyroid Thyroid disease in Simon Forehan the perinatal period Background Thyroid dysfunction affects 2–3% of pregnant women and Thyroid hormone plays a critical role in fetal development. In one in 10 women of childbearing age with normal thyroid pregnancy, increased thyroid hormone synthesis is required to function have underlying thyroid autoimmunity, which may meet fetal needs, resulting in increased iodine requirements. indicate reduced functional reserve.1 Up to 18% of women in Objective the first trimester in Australia are thyroid antibody positive.2 This article outlines changes to thyroid physiology and Thyroid hormone plays a critical role in pregnancy and iodine requirements in pregnancy, pregnancy specific understanding the unique changes to thyroid physiology in reference ranges for thyroid function tests and detection and pregnancy has important implications for the definition and management of thyroid conditions in pregnancy. treatment of thyroid disorders in pregnancy. Discussion Thyroid dysfunction affects 2–3% of pregnant women. Pregnancy specific reference ranges are required to define Thyroid physiology and pregnancy thyroid conditions in pregnancy and to guide treatment. The fetus is dependent on transplacental transfer of maternal thyroxine Overt maternal hypothyroidism is associated with adverse (T4). Deiodination of maternal T4 by the fetus results in local fetal pregnancy outcomes; thyroxine treatment should be production of liothyronine (T3), which is particularly important for commenced immediately in this condition. Thyroxine neurological development.3,4 Maternal T3 does not cross the placenta treatment has also been shown to be effective for pregnant and appears to have little, if any, role in development. Other changes in women with subclinical hypothyroidism who are thyroid pregnancy include an increase in thyroid binding globulin (TBG), resulting peroxidase antibody positive.
    [Show full text]
  • The ART of Assisted Reproductive Technology
    Infertility • THEME The ART of assisted reproductive technology BACKGROUND One in six Australian couples of The Australian Institute of Health and Welfare's reproductive age experience difficulties in National Perinatal Statistical Unit's annual report Jeffrey Persson, conceiving a child. Once a couple has been Assisted reproductive technology in Australia and New MD, FRANZCOG, CREI, is Clinical appropriately assessed, assisted reproductive Zealand 2002, shows that babies born in 2002 using Director (City), technology (ART) techniques can be used to assisted reproductive technology (ART) had longer IVFAustralia. overcome problems with ovulation, tubal patency, gestational ages, higher birth weights and fewer peri- [email protected] male fertility or unexplained infertility. natal deaths than their counterparts of 2 years OBJECTIVE This article discusses the range of previously.1 ART techniques available to subfertile couples. This is the first year national data have been avail- able on the age of women (and their partners) using DISCUSSION Intracytoplasmic sperm injection is now the most common form of ART used in ART. The average age of women undergoing treat- Australia, being used in almost half of all fresh ment in 2002 was 35.2 years, and the average cycles, with in vitro fertilisation being used in age of partners was 37.6 years.1 Age remains the approximately one-third of all fresh cycles. most significant issue affecting a couple's chance of conceiving and carrying a pregnancy to full term. Women need to understand the impact age has on their chance of becoming pregnant. Once a couple has been assessed and investigations suggest subfer- tility, the treatment options depend on the underlying cause (Table 1).
    [Show full text]
  • Postpartum Care of Taiwanese and Chinese Immigrant Women
    City University of New York (CUNY) CUNY Academic Works All Dissertations, Theses, and Capstone Projects Dissertations, Theses, and Capstone Projects 2-2017 Retelling an Old Wife’s Tale: Postpartum Care of Taiwanese and Chinese Immigrant Women Kuan-Yi Chen The Graduate Center, City University of New York How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/gc_etds/1872 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] RETELLING AN OLD WIFE’S TALE: POSTPARTUM CARE OF TAIWANESE AND CHINESE IMMIGRANT WOMEN by KUAN-YI CHEN A dissertation submitted to the Graduate Faculty in Sociology in partial fulfillment of the requirements for the degree of Doctor of Philosophy, The City University of New York 2017 © 2017 Kuan-Yi Chen All Rights Reserved ii Retelling an old wife’s tale: Postpartum care of Taiwanese and Chinese immigrant women by Kuan-Yi Chen This manuscript has been read and accepted for the Graduate Faculty in Sociology in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy ______________________ _____________________________________ Date Barbara Katz Rothman Chair of Examining Committee ______________________ _____________________________________ Date Philip Kasinitz Executive Officer Supervisory Committee: Barbara Katz Rothman Margaret M. Chin Robert Courtney Smith THE CITY UNIVERSITY OF NEW YORK iii ABSTRACT Retelling an old wife’s tale: Postpartum care of Taiwanese and Chinese immigrant women by Kuan-Yi Chen Advisor: Barbara Katz Rothman The focus of this dissertation is the Chinese postpartum tradition zuoyuezi, often translated into English as doing-the-month.
    [Show full text]
  • Breech Presentation at Delivery: a Marker for Congenital Anomaly?
    Journal of Perinatology (2014) 34, 11–15 & 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE Breech presentation at delivery: a marker for congenital anomaly? D Mostello1, JJ Chang2, F Bai2, J Wang3, C Guild4, K Stamps2 and TL Leet2,{ OBJECTIVE: To determine whether congenital anomalies are associated with breech presentation at the time of birth. STUDY DESIGN: A population-based, retrospective cohort study was conducted among 460 147 women with singleton live births using the Missouri Birth Defects Registry, which includes all defects diagnosed during the first year of life. Maternal and obstetric characteristics and outcomes between breech and cephalic presentation groups were compared using w2-square statistic and Student’s t-test. Multivariable binary logistic regression analysis was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULT: At least one congenital anomaly was more likely present among infants breech at birth (11.7%) than in those with cephalic presentation (5.1%), whether full-term (9.4 vs 4.6%) or preterm (20.1 vs 11.6%). The relationship between breech presentation and congenital anomaly was stronger among full-term births (aOR 2.09, CI 1.96, 2.23, term vs 1.40, CI 1.26, 1.55, preterm), but not in all categories of anomalies. CONCLUSION: Breech presentation at delivery is a marker for the presence of congenital anomaly. Infants delivered breech deserve special scrutiny for the presence of malformation. Journal of Perinatology (2014) 34, 11–15;
    [Show full text]
  • Association Between Chorionicity and Preterm Birth in Twin Pregnancies: a Systematic Review Involving 29 864 Twin Pregnancies
    DOI: 10.1111/1471-0528.16479 Systematic Review www.bjog.org Association between chorionicity and preterm birth in twin pregnancies: a systematic review involving 29 864 twin pregnancies S Marleen,a,b C Dias,b R Nandasena,b R MacGregor,c J Allotey,d J Aquilina,c A Khalil,e,f S Thangaratinamg a Barts Research Centre for Women’s Health (BARC), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK b Sri Jayewardenepura Postgraduate Teaching Hospital, Nugegoda, Sri Lanka c Royal London Hospital, Barts Health NHS Trust, London, UK d Institute of Applied Health Research, University of Birmingham, Birmingham, UK e St George’s University Hospitals NHS Foundation Trust, London, UK f Molecular and Clinical Sciences Research Institute, St George’s Medical School, University of London, London, UK g World Health Organization (WHO) Collaborating Centre for Global Women’s Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK Correspondence: S Marleen, Barts Research Centre for Women’s Health (BARC), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Mile End Road, London E1 4NS, UK. Email: [email protected] Accepted 7 August 2020. Published Online 7 October 2020. Background The perinatal mortality and morbidity among twins I2 = 46%, OR 1.55, 95% CI 1.27–1.89 I2 = 68%, OR 1.47, 95% CI vary by chorionicity. Although it is considered that 1.27–1.69, I2 = 60%, OR 1.66, 95% CI 1.43–1.93, I2 = 65%, monochorionicity is associated with an increased risk of preterm respectively).
    [Show full text]